- Home
- UNB vs PBYI Comparison
UNB vs PBYI Comparison
Compare UNB & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- PBYI
- Stock Information
- Founded
- UNB 1891
- PBYI 2010
- Country
- UNB United States
- PBYI United States
- Employees
- UNB N/A
- PBYI N/A
- Industry
- UNB Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- UNB Finance
- PBYI Health Care
- Exchange
- UNB Nasdaq
- PBYI Nasdaq
- Market Cap
- UNB 167.6M
- PBYI 153.2M
- IPO Year
- UNB 1998
- PBYI N/A
- Fundamental
- Price
- UNB $31.26
- PBYI $2.80
- Analyst Decision
- UNB
- PBYI Strong Buy
- Analyst Count
- UNB 0
- PBYI 1
- Target Price
- UNB N/A
- PBYI $7.00
- AVG Volume (30 Days)
- UNB 11.3K
- PBYI 414.1K
- Earning Date
- UNB 01-15-2025
- PBYI 11-07-2024
- Dividend Yield
- UNB 4.57%
- PBYI N/A
- EPS Growth
- UNB N/A
- PBYI 492.79
- EPS
- UNB 1.94
- PBYI 0.47
- Revenue
- UNB $46,385,000.00
- PBYI $243,569,000.00
- Revenue This Year
- UNB N/A
- PBYI N/A
- Revenue Next Year
- UNB N/A
- PBYI N/A
- P/E Ratio
- UNB $16.24
- PBYI $5.91
- Revenue Growth
- UNB N/A
- PBYI 6.30
- 52 Week Low
- UNB $21.00
- PBYI $2.23
- 52 Week High
- UNB $37.70
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- UNB 49.29
- PBYI 46.19
- Support Level
- UNB $31.00
- PBYI $2.72
- Resistance Level
- UNB $35.98
- PBYI $3.12
- Average True Range (ATR)
- UNB 1.44
- PBYI 0.19
- MACD
- UNB -0.54
- PBYI -0.04
- Stochastic Oscillator
- UNB 29.85
- PBYI 20.48
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.